AKT1 and cancer: While there is potential for dasatinib-AKT inhibitor combinations to be useful clinically, the similar level of synergy in both WT and CDH1−/− cells suggests that this combination may not increase the available therapeutic index between normal cells and early CDH1-null cancers.